Outlook Therapeutics (FRA:41O) Change In Receivables : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Change In Receivables?

Outlook Therapeutics's change in receivables for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Outlook Therapeutics's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Outlook Therapeutics's change in receivables for the fiscal year that ended in Sep. 2024 was €0.00 Mil. It means Outlook Therapeutics's Accounts Receivable stayed the same from Sep. 2023 to Sep. 2024 .

Outlook Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Outlook Therapeutics's liquidation value for the three months ended in Dec. 2024 was €-57.34 Mil.

Outlook Therapeutics Change In Receivables Historical Data

The historical data trend for Outlook Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Change In Receivables Chart

Outlook Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Change In Receivables

Get a 7-Day Free Trial

Outlook Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Outlook Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Outlook Therapeutics (FRA:41O) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Outlook Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Outlook Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Outlook Therapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.446	-	64.268	+	0.75 * 0	+	0.5 * 2.969
=	-57.34

Outlook Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

OTLK:USA

Address

111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines